These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Author: Yang L, Hu X, Chai X, Ye Q, Pang J, Li D, Hou T.
    Journal: Drug Discov Today; 2022 Jan; 27(1):326-336. PubMed ID: 34537334.
    Abstract:
    Tuberculosis (TB), an airborne infectious disease mainly caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of human morbidity and mortality worldwide. Given the alarming rise of resistance to anti-TB drugs and latent TB infection (LTBI), new targets and novel bioactive compounds are urgently needed for the treatment of this disease. We provide an overview of the recent advances in anti-TB drug discovery, emphasizing several newly validated targets for which an inhibitor has been reported in the past five years. Our review presents several attractive directions that have potential for the development of next-generation therapies.
    [Abstract] [Full Text] [Related] [New Search]